RESUMEN
We report here our experience with regular automated red cell exchange transfusion for the management of chronic complications of sickle cell disease in 50 patients in our institution from June 2011 to December 2014. The mean sickle hemoglobin level was 44% and 8.5% pre- and post-transfusion, respectively. Platelets were reduced by a mean 70% during the procedure with a count of less than 50 × 109 /l in 6% of cases. The alloimmunization rate was 0.065/100 units of red cells with no hemolytic reactions. Patients with no iron overload at baseline showed no evidence of iron accumulation with a mean liver iron concentration of 1.6 mg/g dry tissue and 1.9 mg/g dry tissue at baseline and 36 months, respectively. All six patients with pre-existing iron overload and on chelation therapy, showed a gradual reduction of their liver iron concentration and two patients could discontinue chelation during the follow-up period. Seventy percentage of patients who were on the programme for recurrent painful crises showed a sustained reduction in the number of emergency hospital attendances; the mean number of days in hospital for emergency treatment was 103 in the year prior to commencing ARCET and reduced to 62 (40%) after the first 12 months, 51 (50%) after 24 months, and 35 days (66%) after 36 months. J. Clin. Apheresis 31:545-550, 2016. © 2015 Wiley Periodicals, Inc.
Asunto(s)
Anemia de Células Falciformes/terapia , Transfusión de Eritrocitos/normas , Automatización , Manejo de la Enfermedad , Transfusión de Eritrocitos/métodos , Humanos , Hierro/metabolismo , Tiempo de Internación , Dolor , Seguridad del Paciente , Recuento de Plaquetas , Resultado del TratamientoRESUMEN
AIMS: Transfused patients with sickle cell disease (SCD) are at risk of iron overload and identifying such patients is important to prevent associated complications. Our aim was to assess the efficacy of serial serum ferritin (SF) measurements in identifying patients with hepatic iron overload as assessed by liver MRI and its usefulness in guiding decision making regarding chelation therapy. PATIENTS/METHODS: We retrospectively compared the results of 49 liver MRI scans (LS) with the median serum ferritin (MSF) values for 28 patients in our institution. RESULTS: We found a nonlinear increment of MSF with increasing liver iron concentration (LIC). 18.4% and 47.4% of abnormal LSs corresponded to MSF <1000 mcg/L and <2000 mcg/L, respectively. 30.4% of patients with LIC of 7 mg/g dry weight or higher had a MSF <2000 mcg/L. In 38.5% of patients receiving chelation, MSF offered little information regarding the efficacy of treatment and was sometimes misleading. CONCLUSION: Serial serum ferritin measurements in adult transfused patients with sickle cell disease have a low sensitivity for identifying patients with iron overload and are of limited value in guiding decision making regarding initiation or monitoring of chelation therapy. The iron status of such high risk patients should be assessed by more definitive ways such as MRI.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Ferritinas/sangre , Sobrecarga de Hierro/diagnóstico , Sobrecarga de Hierro/etiología , Hierro/metabolismo , Hígado/metabolismo , Imagen por Resonancia Magnética , Adulto , Anciano , Anemia de Células Falciformes/terapia , Humanos , Hígado/patología , Persona de Mediana Edad , Estudios Retrospectivos , Sensibilidad y Especificidad , Transferrinas/sangre , Transferrinas/metabolismo , Reacción a la Transfusión , Adulto JovenRESUMEN
Strokes are one of the most severe complications of sickle-cell disease. Most studies have been restricted to children with sickle-cell disease. To better understand the characteristics and follow-up of strokes occurring from childhood to adulthood, we undertook a retrospective cohort study of 69 stroke patients among the 2,875 patients consulting at the French Adult Sickle-Cell Disease Referral Center. Between 1970 and 2008, they had experienced 104 strokes: 80 ischemic, 22 hemorrhagic, and 2 intracranial sinus thromboses. Coma and/or fatal outcomes underscored the severity of strokes in sickle-cell disease patients.Hemorrhagic strokes occurred mostly in adults and carried a higher risk of death than ischemic stroke. The mechanisms underlying sickle-cell disease associated strokes were reevaluated and etiologies were determined for first stroke and recurrences, in childhood and adulthood. Sickle-cell disease vasculopathy concerned only SS patients and remains their most frequent stroke etiology. Cardioembolism, vaso-occlusive crisis and triggering factors were other etiologies identified in adults. Recurrences occurred in 19 SS patients only after a first ischemic stroke. SC patients' strokes occurred in adulthood and were associated with cardiovascular risk factors. Our findings provide novel information about cerebrovascular pathologies throughout the lives of sickle-cell disease patients and suggest the need for different diagnostic and therapeutic management approaches in those different settings.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Accidente Cerebrovascular/etiología , Adulto , Edad de Inicio , Anciano , Isquemia Encefálica/epidemiología , Isquemia Encefálica/etiología , Hemorragia Cerebral/epidemiología , Hemorragia Cerebral/etiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Derivación y Consulta , Estudios Retrospectivos , Factores de Riesgo , Accidente Cerebrovascular/clasificación , Accidente Cerebrovascular/epidemiología , Adulto JovenRESUMEN
Initial management of the acute pain crisis (APC) of sickle cell disease (SCD) is often unsatisfactory, and might be improved by developing a standardised analgesia protocol. Here, we report the first stages in developing a standard oral protocol for adolescents and adults. Initially, we performed a dose finding study to determine the maximal tolerated dose of sublingual fentanyl (MTD SLF) given on arrival in the acute care facility, when combined with repeated doses of oral oxycodone. We used a dose escalation algorithm with two dosing ranges based on patient's weight (<50 kg or >50 kg). We also made a preliminary evaluation of the safety and efficacy of the protocol. The study took place in a large tertiary centre in London, UK. Ninety patients in the age range 14-60 years were pre-consented and 31 treatment episodes were evaluated. The first 21 episodes constituted the dose escalation study, establishing the MTD SLF at 600 mcg (>50 kg) or 400 mcg (<50 kg). Further evaluation of the protocol indicated no evidence of severe opioid toxicity, nor increased incidence of acute chest syndrome (ACS). Between 0 and 6 hours, the overall gradient of reduction of visual analogue pain score (visual analogue scale (VAS)) was 0.32 centimetres (cm) per hour (95% confidence interval (CI) = 0.20 to 0.44, p < 0.001). For episodes on MTD SLF, there was median (interquartile range (IQR)) reduction in VAS score of 2.8 cm (0-4.2) and 59% had at least a 2.6-cm reduction. These results are supportive of further evaluation of this protocol for acute analgesia of APC in a hospital setting and potentially for supervised home management.
RESUMEN
Hydroxyurea-derived clinical and biological benefits and safety were retrospectively studied for 123 adult patients from 2 sickle cell disease referral centers during a total follow-up of 654 patient-years and total hydroxyurea exposure of 549 patient-years. Fifty-six adverse events occurred (incidence: 12%/patient-year), with leg ulcers being the most frequent. Adverse events could arise at any time and were usually reversible. No malignancy was observed. Clinical and biological benefits of our cohort were similar to those previously reported. Based on this relatively long retrospective study, the risk/benefit ratio for moderate hydroxyurea doses was satisfactory.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Hidroxiurea/uso terapéutico , Adolescente , Adulto , Anemia de Células Falciformes/complicaciones , Antidrepanocíticos , Niño , Evaluación de Medicamentos , Femenino , Estudios de Seguimiento , Humanos , Hidroxiurea/efectos adversos , Úlcera de la Pierna/inducido químicamente , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Medición de Riesgo , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Abnormal interactions between red blood cells, leukocytes and endothelial cells play a critical role in the occurrence of the painful vaso-occlusive crises associated with sickle cell disease. We investigated the interaction between circulating leukocytes and red blood cells which could lead to aggregate formation, enhancing the incidence of vaso-occlusive crises. DESIGN AND METHODS: Blood samples from patients with sickle cell disease (n=25) and healthy subjects (n=5) were analyzed by imaging and classical flow cytometry after density gradient separation. The identity of the cells in the peripheral blood mononuclear cell layer was determined using antibodies directed specifically against white (anti-CD45) or red (anti-glycophorin A) blood cells. RESULTS: Aggregates between red blood cells and peripheral blood mononuclear cells were visualized in whole blood from patients with sickle cell disease. The aggregation rate was 10-fold higher in these patients than in control subjects. Both mature red blood cells and reticulocytes were involved in these aggregates through their interaction with mononuclear cells, mainly with monocytes. The size of the aggregates was variable, with one mononuclear cell binding to one, two or several red blood cells. Erythroid Lu/basal cell adhesion molecule and α(4)ß(1) integrin were involved in aggregate formation. The aggregation rate was lower in patients treated with hydroxycarbamide than in untreated patients. CONCLUSIONS: Our study gives visual evidence of the existence of circulating red blood cell-peripheral blood mononuclear cell aggregates in patients with sickle cell disease and shows that these aggregates are decreased during hydroxycarbamide treatment. Our results strongly suggest that erythroid Lu/basal cell adhesion molecule proteins are implicated in these aggregates through their interaction with α(4)ß(1) integrin on peripheral blood mononuclear cells.
Asunto(s)
Anemia de Células Falciformes/metabolismo , Moléculas de Adhesión Celular/metabolismo , Eritrocitos/metabolismo , Integrina alfa4beta1/metabolismo , Sistema del Grupo Sanguíneo Lutheran/metabolismo , Monocitos/metabolismo , Adulto , Anemia de Células Falciformes/tratamiento farmacológico , Anemia de Células Falciformes/genética , Anemia de Células Falciformes/patología , Antidrepanocíticos/administración & dosificación , Agregación Celular/efectos de los fármacos , Células Cultivadas , Técnicas de Cocultivo , Eritrocitos/patología , Femenino , Humanos , Hidroxiurea/administración & dosificación , Masculino , Monocitos/patologíaRESUMEN
The Inforare project aims to set up a system for the sharing of clinical and familial data, in order to study how genes are related to the severity of sickle cell disease. While the computerisation of clinical records represents a valuable research goal, an ethical framework is necessary to guarantee patients' protection and their rights in this developing field. Issues relating to patient information during the Inforare study were analysed by the steering committee. Several major concerns were discussed by the committee and formalized in the patients' information letter: educating patients to aid the recruitment of family members, rules of confidentiality and the disclosure of aggregate, individual and unexpected research results. This paper presents the main issues addressed.
Asunto(s)
Anemia de Células Falciformes/genética , Confidencialidad , Revelación , Sistemas de Registros Médicos Computarizados/ética , Derechos del Paciente , Recolección de Datos/métodos , Ética Médica , Familia , HumanosAsunto(s)
Anemia de Células Falciformes , Transfusión de Eritrocitos/métodos , Hipertensión , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/fisiopatología , Anemia de Células Falciformes/terapia , Transfusión de Eritrocitos/instrumentación , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/sangre , Hipertensión/etiología , Hipertensión/fisiopatología , Hipertensión/terapia , MasculinoRESUMEN
BACKGROUND: Delayed hemolytic transfusion reaction (DHTR) is a life-threatening complication in sickle cell disease (SCD) characterized by recurrence of disease complications, recipient red blood cell (RBC) destruction, and frequently no detectable antibody. Phosphatidylserine (PS) exposure signs suicidal RBC death or eryptosis and is involved in vasoocclusive crisis (VOC). STUDY DESIGN AND METHODS: Transfusion was monitored in 48 SCD patients for up to 20 days. PS exposure was evaluated in vivo on patient RBCs (PS-RBCs) at five time points and in vitro after incubation of donor RBCs with pretransfusion plasma. RESULTS: Three VOC patients displayed DHTR with recurrent SCD features and no detectable antibody in two cases. In vitro, PS-RBC percentage was significantly increased by incubating donor RBCs with pretransfusion plasma samples from DHTR patients with no detectable antibody. No such increase was observed with samples from other patients. This result indicates that donor RBCs may be damaged by the environment of SCD patients, increasing the physiologic clearance of apoptotic RBCs. In vivo, PS-RBC percentage increased in all three cases after destruction of transfused RBCs, indicating that DHTR induces PS-RBCs and, possibly, subsequent VOC and autologous RBC destruction. CONCLUSION: This study clearly demonstrates that DHTR can occur in the absence of detectable antibody. In these cases, a mechanism of excessive eryptosis is proposed.
Asunto(s)
Anemia de Células Falciformes/terapia , Eritrocitos/citología , Hemólisis/inmunología , Reacción a la Transfusión , Adulto , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/inmunología , Muerte Celular , Eritrocitos/inmunología , Femenino , Citometría de Flujo , Humanos , Masculino , Fosfatidilserinas/metabolismo , Síndrome , Adulto JovenRESUMEN
RATIONALE: Steady-state mild pulmonary hypertension is a risk factor for death in adults with sickle cell disease. Acute pulmonary hypertension has been reported during exercise and vasoocclusive pain crisis in these patients. OBJECTIVES: The aim of the present study was to evaluate changes in pulmonary pressures and cardiac biomarkers during severe acute chest syndrome and their associations with mortality. METHODS: We prospectively evaluated 70 consecutive adults who received standardized treatment in our intensive care unit for a total of 84 episodes. At admission, cardiac biomarkers were measured. Transthoracic echocardiography was performed for pulmonary hypertension assessment via measurement of tricuspid regurgitant jet velocity and was repeated when possible after resolution. MEASUREMENTS AND MAIN RESULTS: Tricuspid jet velocity was less than 2.5 m/second in 34 (40%) of the 84 episodes, 2.5 to 2.9 m/second in 19 (23%), and 3 m/second or greater in 31 episodes (37%). Cor pulmonale occurred in 11 (13%) episodes. Tricuspid jet velocity showed significant positive correlations with B-type natriuretic peptide (rho = 0.54, P < 0.01) and cardiac troponin I (rho = 0.42, P < 0.01). Pulmonary pressures increased compared with steady state then decreased after resolution. All five patients who required invasive ventilation and all four patients who died during the immediate hospital course had jet velocity values of 3 m/second or greater. Overall mortality was 12.9% (9 patients) and survival was significantly lower in patients whose jet velocity was 3 m/second or greater during at least one episode, compared with the other patients (P < 0.01). CONCLUSIONS: Pulmonary pressures increase during severe acute chest syndrome, and pulmonary hypertension is associated with cardiac biomarker elevation and a higher risk of death.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Hipertensión Pulmonar/fisiopatología , Enfermedad Cardiopulmonar/fisiopatología , Síndrome de Dificultad Respiratoria/fisiopatología , Adulto , Anemia de Células Falciformes/mortalidad , Anemia de Células Falciformes/fisiopatología , Biomarcadores , Presión Sanguínea , Ecocardiografía , Femenino , Francia , Humanos , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/mortalidad , Masculino , Péptido Natriurético Encefálico/sangre , Estudios Prospectivos , Arteria Pulmonar , Enfermedad Cardiopulmonar/etiología , Enfermedad Cardiopulmonar/mortalidad , Síndrome de Dificultad Respiratoria/etiologíaRESUMEN
Hydroxyurea (HU) is useful for treating sickle cell anemia because of its ability to reduce some of the severe clinical events such as painful crises and acute chest syndrome. It may also reduce the need for blood transfusions and frequent hospitalizations and reduce mortality. Nevertheless, no consistent recommendations regarding its therapeutic schedule are defined. Our aim was to improve and validate a high performance liquid chromatography (HPLC) technique to measure HU and to study HU levels in serum and urine of sickle cell anemia patients and relate this to treatment efficacy and compliance. Thirty-seven patients received 1,128 +/- 333 mg of HU per day (8.0 to 28.0 mg/kg/day). Plasma and/or urine were sampled and HU was measured using an HPLC method coupled with UV detection. We validated a specific, sensitive assay with good reproducibility and linearity, and showed a positive relationship between plasma HU concentrations and time elapsed between oral HU intake and sampling. We observed plasma HU concentrations were positively correlated with change in mean corpuscular volume (MCV) before and during the treatment. No correlation was obtained between HU concentration and Hb F level.